Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
18.06. | Tarsus Pharmaceuticals, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
09.06. | Tarsus Pharmaceuticals auf Goldman Sachs Konferenz: Fokus auf strategisches Wachstum | 3 | Investing.com Deutsch | ||
02.06. | Oppenheimer assumes Tarsus stock at outperform on strong sales | 1 | Investing.com | ||
27.05. | Tarsus Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) | 2 | Benzinga.com | ||
27.05. | H.C. Wainwright sets $72 target for Tarsus stock with Buy rating | 2 | Investing.com | ||
06.05. | 6 Analysts Assess Tarsus Pharmaceuticals: What You Need To Know | 2 | Benzinga.com | ||
02.05. | Tarsus Pharmaceuticals anticipates 85,000-90,000 XDEMVY bottles dispensed in Q2 2025 amid expanded DTC campaign | 1 | Seeking Alpha | ||
01.05. | Tarsus Pharmaceuticals, Inc. GAAP EPS of -$0.64, revenue of $78.3M | 3 | Seeking Alpha | ||
TARSUS PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
01.05. | Tarsus Pharmaceuticals, Inc: Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements | 414 | GlobeNewswire (Europe) | Generated $78.3 million in net product sales of XDEMVY®, an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000 bottles to patients Strengthened financial position... ► Artikel lesen | |
01.05. | Tarsus Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
01.05. | Tarsus Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
30.04. | An Overview of Tarsus Pharmaceuticals' Earnings | 2 | Benzinga.com | ||
24.04. | Tarsus Pharmaceuticals, Inc: Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025 | 1 | GlobeNewswire (USA) | ||
22.04. | Tarsus Pharmaceuticals, Inc: Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 ... | 1 | GlobeNewswire (USA) | ||
13.03. | Tarsus Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
13.03. | Tarsus prices $125M stock offering | 4 | Seeking Alpha | ||
13.03. | Tarsus Pharmaceuticals, Inc: Tarsus Announces Pricing of Upsized $125.0 Million Public Offering | 4 | GlobeNewswire (USA) | ||
12.03. | Tarsus Pharmaceuticals startet Aktienangebot im Wert von 100 Millionen US-Dollar | 3 | Investing.com Deutsch | ||
12.03. | Tarsus Pharmaceuticals, Inc: Tarsus Announces Proposed $100.0 Million Public Offering | 2 | GlobeNewswire (USA) | ||
06.03. | Jefferies raises Tarsus stock target to $58, keeps Buy rating | 6 | Investing.com |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 94,40 | -2,13 % | Biotech-Übernahmekarussell nimmt Fahrt auf! BioNTech, Evotec, Merck & Co., BioNxt Solutions Aktie! | Das Übernahmekarussell dreht sich im Biotech-Sektor wieder schneller. Jüngstes Beispiel ist die Übernahme von Verona Pharma durch Merck. Der US-Konzern lässt sich dies 3 Mrd. USD kosten. Deutlich günstiger... ► Artikel lesen | |
EVOTEC | 7,456 | +0,59 % | Evotec steigt weiter - Partnerschaft entfesselt neue Fantasie! Jetzt lesen!! | ||
CUREVAC | 4,610 | -0,99 % | DAX-Korrektur! BioTech Im Übernahme-Modus! BioNTech, CureVac, Pfizer, Vidac Pharma und Kraft Heinz im Fokus | Die Aktienmärkte zeigen sich in Bestform: Sowohl der DAX als auch der NASDAQ 100 haben in den vergangenen Tagen Muskeln gezeigt. Angetrieben werden die Kurse vor allem von der anhaltenden Stärke der... ► Artikel lesen | |
MODERNA | 27,305 | -2,45 % | Tesla und Moderna: Das sind die Short-Kandidaten von JPMorgan | © Foto: DALL*ETesla und Moderna gehören zu den Aktien, bei denen JPMorgan im zweiten Halbjahr 2025 zu Short-Positionen rät.Zum Start ins zweite Halbjahr ließ Pedro Martins Junior, Co-Leiter der US-Aktienanalyse... ► Artikel lesen | |
STRYKER | 334,90 | -0,15 % | Kurs von Stryker fällt ab (334,4293 €) | Im US-amerikanischen Wertpapierhandel liegt die Aktie von Stryker gegenwärtig im Minus. Der jüngste Kurs betrug 387,52 US-Dollar. Die Aktie von Stryker verzeichnet aktuell einen Kursrückgang von 0,86... ► Artikel lesen | |
VIKING THERAPEUTICS | 27,095 | -2,01 % | Viking Therapeutics: Knallt's jetzt wieder hoch? | Im letzten Jahr war die Viking-Aktie ein großer Biotech-Highflyer an der Börse. Die Euphorie hat sich mittlerweile weitgehend gelegt. Das heißt: Die Aktie ist wieder einen genaueren Blick wert. Viking... ► Artikel lesen | |
SCORPIUS | 0,072 | 0,00 % | Scorpius Holdings, Inc.: Scorpius Holdings Announces Corporate Update Including Cost Optimization Initiatives, Strategic Corporate Developments, and Potential Opportunities for Expansion into Southeast Asia | Operational Realignment Expected to Deliver Over $6 Million in Annual Cost Savings Company Exploring CDMO Expansion Opportunities in Southeast Asia San Antonio, TX, May 04, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
KUROS BIOSCIENCES | 30,660 | -1,60 % | Kuros Biosciences AG: Kuros Biosciences to share latest MagnetOs market impact and strategic priorities at Capital Market Day in Zürich | Kuros Biosciences to share latest MagnetOs market impact and strategic priorities at Capital Markets Day in Zürich
Schlieren (Zürich), Switzerland, May 13, 2025 - Kuros Biosciences ("Kuros"... ► Artikel lesen | |
VAXART | 0,321 | 0,00 % | OTC Markets Group Welcomes Vaxart, Inc. to OTCQX | NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Vaxart, Inc. (OTCQX:... ► Artikel lesen | |
NEUROCRINE BIOSCIENCES | 113,45 | -1,94 % | NBIX: Phase 3 Study Shows CRENESSITY Improves Weight-Related Outcomes In Adrenal Disorder Patients | WASHINGTON (dpa-AFX) - Neurocrine Biosciences Inc. (NBIX) shared new results from a one-year clinical study at the Endocrine Society's 2025 Annual Meeting in San Francisco. The study looked... ► Artikel lesen | |
HALOZYME THERAPEUTICS | 49,170 | -1,36 % | Halozyme Says Bristol-Myers Squibb Gets EC Approval For Opdivo SC Developed With Halozyme's ENHANZE | NEW YORK CITY (dpa-AFX) - Halozyme Therapeutics, Inc. (HALO) Wednesday said that Bristol-Myers Squibb Company (BMY) received approval from the European Commission (EC) for a new subcutaneous... ► Artikel lesen | |
IMMATICS | 5,185 | -3,45 % | Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma | Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33 heavily pretreated patients with metastatic melanoma demonstrates favorable tolerability and promising clinical activity with ongoing... ► Artikel lesen | |
MANNKIND | 3,300 | -1,73 % | H.C. Wainwright assumes coverage on MannKind stock with Buy rating | ||
RELIEF THERAPEUTICS | 2,325 | 0,00 % | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011 | Relief Therapeutics Holding SA / Key word(s): Miscellaneous
Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011
20-Jun-2025 / 07:00 CET/CEST
Release of an ad hoc announcement... ► Artikel lesen | |
BEONE MEDICINES LTD ADR | 256,00 | +2,40 % | BeOne Medicines Ltd.: BeOne Medicines to Announce Second Quarter 2025 Financial Results on August 6 | BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its second quarter 2025 financial results on Wednesday, August 6, 2025 before the financial markets... ► Artikel lesen |